期刊
ARTHRITIS AND RHEUMATISM
卷 64, 期 7, 页码 2311-2318出版社
WILEY
DOI: 10.1002/art.34402
关键词
-
类别
资金
- National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH [R01-AR-49772]
- Mary Kirkland Center for Lupus Research
- Barbara Volcker Center for Women and Rheumatic Disease
- Rheuminations, Inc.
- National Center for Research Resources, NIH [1UL1-RR-029893]
Objective To investigate which serologic and clinical findings predict adverse pregnancy outcome in patients with antiphospholipid antibody (aPL) and to test the hypothesis that a pattern of clinical and serologic variables can identify women at highest risk of adverse pregnancy outcome. Methods Women enrolled in a multicenter prospective observational study of risk factors for adverse pregnancy outcome in patients with aPL (lupus anticoagulant [LAC], anticardiolipin antibody [aCL], and/or antibody to beta 2-glycoprotein I [anti-beta 2GPI]) and/or systemic lupus erythematosus (SLE) were recruited for the present prospective study. Demographic, clinical, serologic, and treatment data were recorded at the time of the first study visit. The relationship between individual and combined variables and adverse pregnancy outcome was assessed by bivariate and multivariate analysis. Results Between 2003 and 2011 we enrolled 144 pregnant patients, of whom 28 had adverse pregnancy outcome. Thirty-nine percent of the patients with LAC had adverse pregnancy outcome, compared to 3% of those who did not have LAC (P < 0.0001). Among women with IgG aCL at a level of =40 units/ml, only 8% of those who were LAC negative had adverse pregnancy outcome, compared to 43% of those who were LAC positive (P = 0.002). IgM aCL, IgG anti-beta 2GPI, and IgM anti-beta 2GPI did not predict adverse pregnancy outcome. In bivariate analysis, adverse pregnancy outcome occurred in 52% of patients with and 13% of patients without prior thrombosis (P = 0.00005), and in 23% with SLE versus 17% without SLE (not significant); SLE was a predictor in multivariate analysis. Prior pregnancy loss did not predict adverse pregnancy outcome. Simultaneous positivity for aCL, anti-beta 2GPI, and LAC did not predict adverse pregnancy outcome better than did positivity for LAC alone. Conclusion LAC is the primary predictor of adverse pregnancy outcome after 12 weeks' gestation in aPL-associated pregnancies. Anticardiolipin antibody and anti-beta 2GPI, if LAC is not also present, do not predict adverse pregnancy outcome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据